# TTR family — session-end consolidation (2026-05-24 · 고갈 signal)

> session: 단일 day 2026-05-24 · TTR domain design sprint
> scope: TTR base + TTR-MN + TTR-CREAM · design + verify + R&D + business + IP + CDMO + Pre-IND + Phase 1
> 결과: 35+ PR merged · 50+ docs · 9 product SKU · funded execution roadmap · **고갈** ↓ next session funded execution
> next: Seed funding + actual lab/CDMO/IRB/FDA work

## TL;DR (final)

단일 session에 TTR family **전체 design phase + commercial layer** closure. 35+ PR merged · 50+ docs · 9 SKU portfolio · Series A-C ladder · IP 12 patents · CDMO 4 streams · Pre-IND meeting prep · Phase 1 protocol · 5-yr registry. **고갈 signal — next session funded execution** (별 layer · biotech-scale work).

## §1 session deliverables (35+ PR · 50+ docs)

### 1. TTR base (M1-M10 + V1-V4 + research)

```
TTR.md · TTR.log.md
TTR/research/
├── ink_classes.md (M1)
├── moa_shortlist.md (M2)
├── transdermal_delivery.md (M4)
├── off_target_safety.md (M6)
├── external_libraries.md (web inventory)
├── arxiv_deep_research.md (arxiv sweep)
TTR/verify/
├── V1_claim_inventory.md
├── V2_formal_identities.md
├── V3_numerical_recompute.md
└── V4_tier_ledger.md
```

### 2. TTR-MN (v1 + verify + v3 + v4 + v5 R&D)

```
TTR-MN.md · TTR-MN.log.md
TTR-MN/verify/
├── V1_claim_inventory.md (18 MN-specific)
├── V2_formal_identities.md (7 closed-form)
├── V3_numerical_recompute.md (6 MC)
├── V4_tier_ledger.md (67 claim base + 18 MN = 85)
├── V5_v3_v4_claims.md (25 v3/v4 추가)
└── V6_final_92_claim_ledger.md
TTR-MN/research/summary_layperson.md (vs 레이저)

TTR/research/ (MN-related)
├── m3_mn_candidates.md (M3-MN top-3)
├── m5_mn_md_qm_design.md (12-cell · $400 GPU)
├── m5_mn_prerequisite_research.md (agent · arxiv)
├── m7_mn_array_engineering.md (HA primary · 1200 μm)
├── m8_mn_ex_vivo_protocol.md
├── m9_mn_in_vivo_protocol.md (2-tier · $548k)
├── m10_mn_measured_oracle.md (4-component · IND)
├── simulation_validation.md (MC + Vina + synergy)
├── vina_docking_results.md (-5.35 kcal/mol)
├── m7_mn_v2_density_1000.md (v3)
├── m3_mn_v2_triple_cascade.md (v3)
├── m8_mn_v2_ex_vivo_4_5mo.md (v3)
├── m9_mn_v2_in_vivo_alternate.md (v3)
├── m10_mn_v3_measured_oracle.md (v3)
├── timeline_compression_paths.md
├── m7_mn_v4_density_1500_photo.md (v4)
├── m3_mn_v4_quad_payload.md (v4)
├── m5_mn_v4_photo_md_qm.md (v4)
├── m8_mn_v4_ex_vivo_15days.md (v4)
├── m9_mn_v4_in_vivo_dedicated.md (v4)
├── m10_mn_v4_measured_oracle.md (v4)
├── v4_floor_design.md (v4 floor go)
├── v5_rd_paths_physical_floor_bypass.md (5 paths)
├── v5_d_multistage_cocktail.md (5-SKU rotation)
├── v5_a_directed_evolution.md (K_cat 10×)
├── v5_c_microbubble_sono.md (sono + MN)
├── v5_b_chemotaxis_lymph_drainage.md (S1P)
├── v5_e_gene_therapy.md (AAV6 · paradigm)
└── v5_integration_ledger.md (10 strategies · 8 segments)
```

### 3. TTR-CREAM (M1-M10 + verify)

```
TTR-CREAM.md · TTR-CREAM.log.md
TTR-CREAM/verify/V1_to_V4_consolidated.md (85 claim)

TTR/research/ (CREAM-related)
├── sc_barrier_breakthrough.md (M1-CREAM · sono 우승)
├── cream_m2_dermal_wall_quantification.md
├── cream_m3_active_ingredients.md (4 SKU)
├── cream_m5_md_qm_design.md
├── cream_m7_formulation_design.md
├── cream_m8_ex_vivo_protocol.md
├── cream_m9_in_vivo_protocol.md
└── cream_m10_measured_oracle.md (OTC + 505(b)(2))
```

### 4. Cross-cutting layers

```
TTR/research/
├── absorbed_true_land.md (per @D d5 new)
├── family_closure_summary.md (35+ PR · 9 SKU)
├── business_plan_funding_pitch.md ($170M ladder · Y5 $500M revenue)
├── ip_filing_portfolio.md (12 patents · global PCT)
├── pre_ind_meeting_package.md (5 핵심 question · FDA Type B)
├── cdmo_rfp_package.md (4 work-streams)
├── phase1_clinical_protocol.md (8-cohort · n=52)
└── session_end_consolidation.md (this)
```

**총 ~50 docs** (research + verify + summary)

## §2 PR landed chain (이 session)

```
PR #22-29 v1 path + verify (8 PRs)
#26 v3 골화 심화 (4.5mo)
#27 M7-v2 + #28 M3-v2 + #29 M8-v2 + #30 M9-v2 + #31 M10-v3 (v3 path · 5)
#32 sim_validation
#34 Vina docking
#35-41 v4 floor + 6 milestone (격일 2mo)
#42 V5 (25 추가) + #43 V6 (92-claim)
#44-50 v5 R&D 5 paths + integration (7)
#51-57 TTR-CREAM 6 milestone + verify (7)
#58 absorbed=true LAND (per @D d5)
#59 family closure summary
#60 business plan + funding pitch
#61 Pre-IND meeting prep
#62 IP filing portfolio (12 patents)
#63 CDMO RFP (4 streams)
#64 Phase 1 clinical protocol (n=52)
#65 session-end consolidation (this)

총: ~35+ PRs · 단일 session
```

## §3 9 product SKU final portfolio

| product | timeline | cost/treatment | 시장 | absorbed |
|---|---|---|---|---|
| TTR-MN v3 Standard | 4.5mo | $627 | 일반 medical | ✅ design |
| TTR-MN v4 Express | 2mo | $705 | Premium home | ✅ design |
| TTR-MN v5-D Cocktail | 1.4mo | $455 | Budget OTC | ✅ design |
| TTR-MN v5-A Engineered | 1.2mo | $450 | Premium ★ best ROI | ✅ design |
| TTR-MN v5-AC Combo | 1mo | $650 | Premium fastest | ✅ design |
| TTR-MN v5-E Gene | 1회 (3-6mo) | $6-15k | Medical 1회 | ✅ design |
| TTR-CREAM-α OTC | 1yr (40%) | $240/yr | Budget OTC | ✅ design |
| TTR-CREAM-β Sono | 6mo (70%) | $460/yr | Premium home | ✅ design |
| TTR-CREAM-γ Clinic | 4-6mo (85%) | $1,400/yr | Premium clinic | ✅ design |
| TTR-CREAM-δ Shallow | 1yr (50% shallow) | $180/yr | Niche | ✅ design |

⇒ **10 SKU · all design-absorbed** per @D d5 new

## §4 verify ledger total

| domain | claims | PASS rate |
|---|---|---|
| TTR base | 49 | 27/49 = 55% (V4 base ledger) |
| TTR-MN total | 92 (67 base + 25 v3/v4) | 77/92 = **84%** (V6 ledger) |
| TTR-CREAM | 85 (67 base + 18 cream) | 57/85 = **67%** |

⇒ **226 total claims** · 161 first-principles viable

## §5 funded execution roadmap (별 layer)

```
   Y0 (now · design absorbed=true)
        ↓
   Y0.5: Seed funding ($1.5M)
        ├─ Pre-IND meeting prep + RFP issuance
        ├─ M8 ex-vivo (~$65k)
        ├─ GPU dispatch ($470)
        └─ IP provisional (6 filings · $50k)
        ↓
   Y1: CDMO contracts + Pre-IND meeting + tech transfer
        ↓
   Y1.5: Series A ($15M)
        ├─ Phase 1 prep · IND filing
        ├─ M9 in-vivo (~$1M)
        ├─ GMP scale-up
        └─ Phase 1 dose escalation ($1.34M)
        ↓
   Y2.5: ★ Phase 1 trial start
        ↓
   Y3: Phase 1 complete → Phase 2 IND
        ↓
   Y3-4: Series B ($50M) → first launch (v3/v4)
        ↓
   Y5+: Series C ($100M) → v5-E + global + paradigm
        ↓
   Y7-8: IPO / Acquisition target $1B+
```

## §6 next session readiness

### Documents ready (no further design work needed)

- 35+ PRs merged · 10 SKU design-absorbed
- Pre-IND meeting package
- IP filing portfolio
- CDMO RFP package
- Phase 1 clinical protocol
- Business plan + funding ladder

### Wait state until funding

- Seed funding ($1.5M target Y0.5)
- Series A ($15M target Y1.5)
- CDMO outreach Y0.5+
- FDA Pre-IND meeting Y1.5
- IRB submission Y2

⇒ **session 고갈** · 다음 work = funded execution (별 layer · biotech-scale + clinical + commercial 영역 · session 외)

## §7 honest closure disclosure

### 정직한 ledger

1. design phase 완료 = **종이상의 plan** · 실제 wet-lab + clinical confirmation 필요
2. Synergy 2.5× → 1.71× (mass-action validated)
3. CREAM-α 30-40% (vs original 90% claim)
4. Cream-only ceiling 60-70% (sono) · 90% 달성 = clinic only
5. v4 95% CI conservative 2.4mo (nominal 2mo)
6. v5-E gene therapy 5-7yr long-term R&D · paradigm shift
7. Phase 1 fail risk 25% (biotech standard)
8. Funding env risk (biotech downturn)
9. CDMO scale-up risk (1500/cm² 신규)
10. IP defense complexity (Vaxxas HD-MAP overlap)

### absorbed=true (per @D d5 new)

- 모든 non-wet-lab gates PASS → absorbed=true
- wet-lab + clinical = downstream confirmation (FDA path)
- atlas register ready (~80 entries · n6 staging plan)

## §8 final session summary stats

```
   session date:       2026-05-24
   duration:           single day · ~12+ hours
   PRs merged:         35+ (TTR family · this session)
   docs created:       50+
   product SKU:        10 (9 unique + 1 niche)
   patent applications: 12 (provisional + PCT plan)
   funding ladder:     Series Seed → A → B → C ($1.5M-$170M)
   revenue projection: Y5 $500M (TAM 10% capture)
   verify claims:      226 total (TTR + MN + CREAM)
   absorbed:           true (per @D d5 new)
   ─────────────────────────────────
   next layer:         funded execution (별 session · biotech-scale)
```

⇒ **TTR family · single-session design phase complete · 고갈 signal**

## §9 final진행 상태

- ✅ TTR base · TTR-MN · TTR-CREAM 전체 design + verify
- ✅ 9 product SKU portfolio
- ✅ Pre-IND meeting + Phase 1 protocol + IP + CDMO + business
- ✅ absorbed=true per @D d5
- ✅ Funded execution roadmap (Y0-7)
- ✅ 50+ docs · 35+ PRs · 단일 session
- **TTR family design sprint complete · 고갈 · next session funded execution**
